Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer

Francisco J. Esteva, MD, PhD
Published: Tuesday, Jul 03, 2018



Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Updated findings from the ExteNET trial presented at the 2018 ASCO Annual Meeting showed that the earlier neratinib therapy is given, the better the results are at 6 to 12 months and 12 to 18 months. Previously, the trial reported an improvement in disease-free survival, particularly in patients with estrogen receptor-positive disease. In a 5-year follow-up, treatment with neratinib reduced the risk of invasive disease recurrence or death by 27% compared with placebo as extended adjuvant therapy for patients with HER2-positive early-stage breast cancer following 12 months of trastuzumab (Herceptin).

Neratinib was approved in July 2017 for the extended adjuvant treatment of patients with early-stage, HER2-positive breast cancer following postoperative trastuzumab. The approval was based on phase III results from the ExteNET trial.


Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Updated findings from the ExteNET trial presented at the 2018 ASCO Annual Meeting showed that the earlier neratinib therapy is given, the better the results are at 6 to 12 months and 12 to 18 months. Previously, the trial reported an improvement in disease-free survival, particularly in patients with estrogen receptor-positive disease. In a 5-year follow-up, treatment with neratinib reduced the risk of invasive disease recurrence or death by 27% compared with placebo as extended adjuvant therapy for patients with HER2-positive early-stage breast cancer following 12 months of trastuzumab (Herceptin).

Neratinib was approved in July 2017 for the extended adjuvant treatment of patients with early-stage, HER2-positive breast cancer following postoperative trastuzumab. The approval was based on phase III results from the ExteNET trial.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x